SEC Comment Letter 0000000000-23-001601 to TC BioPharm (Holdings) plc (TCBP, TCBPW) (CIK 0001872812) (TCBPY)

TC BioPharm (Holdings) plc (TCBP, TCBPW) (CIK 0001872812)
Date: Feb. 16, 2023 · CIK: 0001872812 · Accession: 0000000000-23-001601

View on Edgar

AI Filing Summary & Sentiment

Date

February 16, 2023

Author

Not clearly detected

Form

UPLOAD

Company

TC BioPharm (Holdings) plc (TCBP, TCBPW) (CIK 0001872812)

Letter

United States securities and exchange commission logo February 16, 2023 Bryan Kobel Chief Executive Officer TC BioPharm (Holdings) plc Maxim 1, 2 Parklands Way Holytown, Motherwell, ML1 4WR Scotland, United Kingdom Re:TC BioPharm (Holdings) plc Draft Registration Statement on Form F-1 Submitted February 10, 2023 CIK No. 0001872812 Dear Bryan Kobel: This is to advise you that we do not intend to review your registration statement. We request that you publicly file your registration statement no later than 48 hours prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at (202) 551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Richard A. Friedman, Esq.

Show Raw Text

United States securities and exchange commission logo
February 16, 2023
Bryan Kobel
Chief Executive Officer
TC BioPharm (Holdings) plc
Maxim 1, 2 Parklands Way
Holytown, Motherwell, ML1 4WR
Scotland, United Kingdom
Re:TC BioPharm (Holdings) plc
Draft Registration Statement on Form F-1
Submitted February 10, 2023
CIK No. 0001872812
Dear Bryan Kobel:
            This is to advise you that we do not intend to review your registration statement.
            We request that you publicly file your registration statement no later than 48 hours prior
to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for
acceleration.  We remind you that the company and its management are responsible for the
accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or
absence of action by the staff.
            Please contact Tim Buchmiller at (202) 551-3635 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Richard A. Friedman, Esq.

SecProbe.io